PEREGRINE ANNOUNCES COMPLETION OF PATIENT ENROLLMENT AND DOSING IN TARVACIN TRIAL
Peregrine Pharmaceuticals has completed planned patient enrollment and dosing in its initial Phase I clinical trial for Tarvacin Anti-Viral in the treatment of chronic hepatitis C virus infection (HCV). The single-dose-ascending trial was conducted in patients with chronic HCV who have either failed or no longer respond to standard of care treatment. Findings are expected to support the initiation of repeat dose and combination therapy trials later this year.
Tarvacin Anti-Viral is a monoclonal antibody with unique antiviral properties that is in preclinical studies for pandemic and seasonal influenza, cytomegalovirus, HIV and biodefense applications.